4Dx Information

Nearly all lung pathologies are associated with regional changes in airflow throughout the lungs. Yet the current gold standard diagnostics yield average results over the entire lung – and for loss of total lung function to even be measurable, local disease must be advanced. It is critical to detect even subtle functional losses long before lung structure is irreversibly affected by disease - in all lung locations and throughout the respiratory cycle - so that treatment is applied earlier. Now for the first time in medical history, the capability to do that is here. We are 4Dx - a medical technology company formed to commercialize XV Technology™, the first-ever, breakthrough imaging platform that quantitatively measures the patterns of regional lung function. Ultra low dose. Non-invasive. Utilizing existing hospital equipment. 4Dx was founded in Melbourne, Australia, conceived by 4Dx CEO Andreas Fouras and developed by his research group, the Laboratory for Dynamic Imaging at Monash University, and members of the 4Dx team. 4Dx has successfully proven and patented its technology with over 10 years of studies, as well as preclinical and clinical trials - all completed by some of the most talented, top minds within the field of medical technology. Having raised millions of dollars in research funding from agencies including Australia’s National Health & Medical Research Council and the American Asthma Foundation, the team has positioned itself as an unrivaled leader in the race to deliver a world changing medical technology breakthrough.